Regenxbio (RGNX) Total Current Liabilities (2014 - 2025)

Regenxbio's Total Current Liabilities history runs 12 years deep, the most recent figure standing at $118.1 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 14.44% year-over-year to $118.1 million in Q4 2025; TTM through Dec 2025 was $118.1 million, a 14.44% increase from a year earlier, with the FY2025 full-year figure at $118.1 million, up 14.44% from the prior year.
• Total Current Liabilities retreated to $118.1 million in Q4 2025 per RGNX's latest filing, from $124.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $130.5 million in Q4 2021 and bottomed at $84.0 million in Q1 2021.
• The 5-year median for Total Current Liabilities is $116.2 million (2022), against an average of $113.6 million.
• Across the five-year window, Total Current Liabilities soared 164.12% in 2021 and retreated 20.79% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $130.5 million in 2021, then fell by 0.03% to $130.4 million in 2022, then decreased by 0.12% to $130.3 million in 2023, then dropped by 20.79% to $103.2 million in 2024, then advanced by 14.44% to $118.1 million in 2025.
• Per Business Quant, the three latest RGNX Total Current Liabilities figures stand at $118.1 million (Q4 2025), $124.6 million (Q3 2025), and $119.5 million (Q2 2025).